Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon Open-Label Extension in Moderate-to-Severe Alzheimer's
NCT01066546Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Apr 2010
- Primary completion
- Jul 2010
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of latrepirdine in Alzheimer's disease (AD), sponsored by Pfizer. Started Apr 2010; status: terminated.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01066546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01066546.